JP6290100B2 - ビロキサジンの緩和放出製剤 - Google Patents

ビロキサジンの緩和放出製剤 Download PDF

Info

Publication number
JP6290100B2
JP6290100B2 JP2014556658A JP2014556658A JP6290100B2 JP 6290100 B2 JP6290100 B2 JP 6290100B2 JP 2014556658 A JP2014556658 A JP 2014556658A JP 2014556658 A JP2014556658 A JP 2014556658A JP 6290100 B2 JP6290100 B2 JP 6290100B2
Authority
JP
Japan
Prior art keywords
viloxazine
formulation
release
sustained release
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014556658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506980A5 (cg-RX-API-DMAC7.html
JP2015506980A (ja
Inventor
エル． ビエイラ，マイケル
エル． ビエイラ，マイケル
ピー． バート，パッドマナブー
ピー． バート，パッドマナブー
ビー． ファン，オースティン
ビー． ファン，オースティン
Original Assignee
スパーナス ファーマシューティカルズ インコーポレイテッド
スパーナス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47741312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6290100(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by スパーナス ファーマシューティカルズ インコーポレイテッド, スパーナス ファーマシューティカルズ インコーポレイテッド filed Critical スパーナス ファーマシューティカルズ インコーポレイテッド
Publication of JP2015506980A publication Critical patent/JP2015506980A/ja
Publication of JP2015506980A5 publication Critical patent/JP2015506980A5/ja
Application granted granted Critical
Publication of JP6290100B2 publication Critical patent/JP6290100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP2014556658A 2012-02-08 2013-02-07 ビロキサジンの緩和放出製剤 Active JP6290100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596458P 2012-02-08 2012-02-08
US61/596,458 2012-02-08
PCT/US2013/025121 WO2013119794A1 (en) 2012-02-08 2013-02-07 Modified release formulations of viloxazine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018946A Division JP6510093B2 (ja) 2012-02-08 2018-02-06 ビロキサジンの緩和放出製剤

Publications (3)

Publication Number Publication Date
JP2015506980A JP2015506980A (ja) 2015-03-05
JP2015506980A5 JP2015506980A5 (cg-RX-API-DMAC7.html) 2016-01-21
JP6290100B2 true JP6290100B2 (ja) 2018-03-07

Family

ID=47741312

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014556658A Active JP6290100B2 (ja) 2012-02-08 2013-02-07 ビロキサジンの緩和放出製剤
JP2018018946A Active JP6510093B2 (ja) 2012-02-08 2018-02-06 ビロキサジンの緩和放出製剤
JP2019066455A Active JP6832973B2 (ja) 2012-02-08 2019-03-29 ビロキサジンの緩和放出製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018018946A Active JP6510093B2 (ja) 2012-02-08 2018-02-06 ビロキサジンの緩和放出製剤
JP2019066455A Active JP6832973B2 (ja) 2012-02-08 2019-03-29 ビロキサジンの緩和放出製剤

Country Status (8)

Country Link
US (9) US9358204B2 (cg-RX-API-DMAC7.html)
EP (2) EP2812074B1 (cg-RX-API-DMAC7.html)
JP (3) JP6290100B2 (cg-RX-API-DMAC7.html)
AU (4) AU2013217013B2 (cg-RX-API-DMAC7.html)
CA (1) CA2864088C (cg-RX-API-DMAC7.html)
ES (1) ES2950875T3 (cg-RX-API-DMAC7.html)
MX (2) MX356727B (cg-RX-API-DMAC7.html)
WO (1) WO2013119794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
ES2950875T3 (es) * 2012-02-08 2023-10-16 Supernus Pharmaceuticals Inc Formulaciones de liberación modificada de viloxazina
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
US20240041893A1 (en) * 2023-10-03 2024-02-08 Innovate Therapeutics Llc An Extended-Release Pharmaceutical Formulation of Viloxazine And Process For Preparation Thereof
KR20250094621A (ko) * 2023-12-18 2025-06-25 주식회사 아스트로젠 (s)-빌록사진 또는 이의 염의 개선된 제조 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
FR2453639A1 (fr) 1979-04-09 1980-11-07 Sanofi Sa Composition medicamenteuse a liberation programmee immediate-retard a base de naftidrofuryl
US4260606A (en) 1979-07-19 1981-04-07 A. H. Robins Company, Inc. 3-Methyleneazetidine derivatives
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
CA2431041A1 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002087549A1 (fr) * 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
MXPA05008843A (es) * 2003-02-21 2005-10-18 Lek Pharmaceuticals Sistema terapeutico que comprende amoxicilina y acido clavulanico.
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
US7119031B2 (en) * 2004-06-28 2006-10-10 Micron Technology, Inc. Methods of forming patterned photoresist layers over semiconductor substrates
DE102004035938A1 (de) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
US7288347B2 (en) 2004-08-31 2007-10-30 Xerox Corporation Method of applying spot varnish to xerographic image and emulsion aggregation toners for use therein
MX2007012947A (es) * 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007026219A2 (en) 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
EP2457563B1 (en) * 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
AU2007319141B2 (en) * 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
WO2009073118A1 (en) * 2007-12-04 2009-06-11 Merck & Co., Inc. Tryptamine sulfonamides as 5-ht6 antagonists
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
MX2011011579A (es) * 2009-04-30 2012-01-27 Supernus Pharmaceuticals Inc Metodo de tratamiento contra la depresion.
WO2011008298A2 (en) 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
ES2950875T3 (es) * 2012-02-08 2023-10-16 Supernus Pharmaceuticals Inc Formulaciones de liberación modificada de viloxazina

Also Published As

Publication number Publication date
AU2017206245B2 (en) 2019-05-16
AU2017206245A1 (en) 2017-08-10
JP6510093B2 (ja) 2019-05-08
US20130202661A1 (en) 2013-08-08
AU2019216707B2 (en) 2020-10-22
US20160279136A1 (en) 2016-09-29
EP2812074B1 (en) 2023-05-10
US9358204B2 (en) 2016-06-07
US20250222004A1 (en) 2025-07-10
JP2018090601A (ja) 2018-06-14
US20170258801A1 (en) 2017-09-14
AU2013217013B2 (en) 2017-04-20
AU2020233746B2 (en) 2023-09-14
AU2020233746A1 (en) 2020-10-08
ES2950875T3 (es) 2023-10-16
JP2019123736A (ja) 2019-07-25
CA2864088C (en) 2020-04-28
CA2864088A1 (en) 2013-08-15
US20160256465A1 (en) 2016-09-08
JP6832973B2 (ja) 2021-02-24
EP2812074A1 (en) 2014-12-17
US10265319B2 (en) 2019-04-23
WO2013119794A1 (en) 2013-08-15
US9662338B2 (en) 2017-05-30
US20190201407A1 (en) 2019-07-04
AU2013217013A1 (en) 2014-08-28
US20250228859A1 (en) 2025-07-17
MX2023003000A (es) 2023-04-05
EP4233915A3 (en) 2023-09-20
US20230381191A1 (en) 2023-11-30
JP2015506980A (ja) 2015-03-05
US20250367208A1 (en) 2025-12-04
AU2019216707A1 (en) 2019-09-05
US9603853B2 (en) 2017-03-28
MX356727B (es) 2018-06-12
MX2014009528A (es) 2014-11-25
EP4233915A2 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP6832973B2 (ja) ビロキサジンの緩和放出製剤
JP2013249305A (ja) 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
CA2718257A1 (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP6588948B2 (ja) Ｃｎｓ化合物の安定化製剤
EP3184101A1 (en) Levodopa and carbidopa modified release composition

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140919

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180207

R150 Certificate of patent or registration of utility model

Ref document number: 6290100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250